SAN DIEGO--(BUSINESS WIRE)--May 22, 2006--Santarus, Inc. (NASDAQ:SNTS - News), a specialty pharmaceutical company focused on therapies for gastrointestinal diseases and disorders, today announced that new clinical data were presented in a poster session at the Digestive Diseases Week (DDW) meeting on May 21, 2006. The clinical study evaluated nighttime gastric acidity in patients with nocturnal symptoms of gastroesophageal reflux disease (GERD) who were treated with ZEGERID® (omeprazole/sodium bicarbonate) Powder for Oral Suspension 40 mg, Nexium® (esomeprazole magnesium) delayed-release capsules 40 mg and Prevacid® (lansoprazole) delayed-release capsules 30 mg on an empty stomach at bedtime. The results indicated that patients treated with ZEGERID experienced significantly fewer episodes of nocturnal acid breakthrough (NAB) than with the comparator drugs, and that dosing ZEGERID at bedtime on an empty stomach provided more rapid control of gastric acid in the first half of the night, a critical period for acid control.
